Why This Study Matters
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid tumors, and its biology is dominated by a single oncogene: mutant KRAS is present in more than 90% of cases, with the G12D substitution the most common variant. For decades KRAS was considered "undruggable," and first-line chemotherapy with gemcitabine plus nab-paclitaxel produces objective responses in only about a quarter of patients, with median survival under a year. KRAS-G12D-mutant disease specifically has been associated with a worse prognosis than other KRAS variants (external sources).
Most KRAS-G12D inhibitors in development are oral small molecules whose usefulness is constrained by gastrointestinal toxicity and inconsistent tumor exposure. HRS-4642 takes a different route: it is a high-affinity, noncovalent KRAS-G12D inhibitor formulated as a liposomal nanoparticle for intravenous administration, engineered to accumulate in tumor tissue and prolong target inhibition.
Study Design
This was an open-label, single-arm phase 1b/2 study of HRS-4642 combined with nab-paclitaxel and gemcitabine (the "AG" backbone) in advanced KRAS-G12D-mutant PDAC. The phase 1b portion established the recommended phase 2 dose, and the phase 2 portion evaluated efficacy, with confirmed objective response rate in treatment-naive patients as the primary endpoint. HRS-4642 was dosed at 500 mg on day 1 and 1,200 mg on day 8 of each 21-day cycle.
Patient Population
As of the December 5, 2025 data cutoff, 68 patients had been screened and 31 were enrolled and treated — 1 previously treated patient and 30 treatment-naive patients. The efficacy analysis for the primary endpoint was conducted in the 30 treatment-naive patients. An earlier data cutoff (April 10, 2025) reported at ESMO 2025 (abstract 2215O) described the same 31-patient population with a comparable 63% confirmed response rate, providing an independent, consistent read of the primary signal.
Primary Endpoint Results
The trial met its primary endpoint: the confirmed objective response rate was 63.3% (95% CI, 43.9-80.1) among the 30 treatment-naive patients, at a median follow-up of 12.3 months (95% CI, 12.2-13.0). For context, gemcitabine plus nab-paclitaxel alone has historically produced an objective response rate of roughly 23% in advanced PDAC — so the addition of HRS-4642 was associated with a response rate about 2.7 times higher, albeit in a single-arm study rather than a head-to-head comparison (historical comparator from external sources).
The comparison to the ~23% historical chemotherapy response rate is a cross-study benchmark, not a randomized within-trial contrast. A confirmatory randomized trial is required to establish the true added benefit of HRS-4642.
Subgroup Analyses
The available primary source (abstract) reports the confirmed response rate for the overall treatment-naive efficacy population and does not provide subgroup-level response statistics (for example by prior therapy, tumor burden, or metastatic site). No subgroup hazard ratios, confidence intervals, or p-values are reported and none are asserted here.
Safety Profile
Grade ≥3 treatment-related adverse events occurred in 90.3% of treated patients and were primarily hematologic — a profile consistent with the gemcitabine/nab-paclitaxel chemotherapy backbone rather than a novel toxicity signal from HRS-4642. Importantly, no treatment-related adverse events led to treatment discontinuation or death, and no dose-limiting toxicities were seen in phase 1b.
| Parameter | Result |
|---|---|
| Dose-limiting toxicities (phase 1b) | None |
| Recommended phase 2 dose | 500 mg d1 + 1,200 mg d8, q3w |
| Grade ≥3 treatment-related AEs | 90.3% |
| Predominant grade ≥3 AE type | Hematologic |
| TRAEs leading to discontinuation | 0 |
| TRAEs leading to death | 0 |
| Measure | HRS-4642 + AG | AG alone (historical) |
|---|---|---|
| Confirmed ORR | 63.3% (95% CI, 43.9-80.1) | ~23% |
| Median follow-up | 12.3 mo (95% CI, 12.2-13.0) | — |
| Population | 30 treatment-naive, G12D+ | Advanced PDAC |
Interpretation and Broader Context
HRS-4642 is one of the first KRAS-G12D-directed agents to show a clear efficacy signal when added to standard chemotherapy in first-line pancreatic cancer, and its intravenous, liposomal-nanoparticle design is a deliberate attempt to sidestep the exposure and tolerability limits of oral G12D inhibitors. A confirmed response rate above 60% in a disease where chemotherapy alone rarely exceeds 25% is a striking early signal, and the absence of discontinuation- or death-level treatment-related toxicity is reassuring given the aggressive chemotherapy backbone.
The usual caveats for early-phase, single-arm data apply: the sample is small, follow-up is still maturing, and survival endpoints were not the primary readout. The developer has moved the program toward a randomized, placebo-controlled phase 3 comparing HRS-4642 plus AG against placebo plus AG in first-line advanced or metastatic pancreatic cancer (NCT07232875), which will be the true test of whether this response signal translates into a survival benefit.
In a phase 1b/2 trial, the intravenous KRAS-G12D inhibitor HRS-4642 added to gemcitabine and nab-paclitaxel met its primary endpoint with a confirmed 63.3% response rate in treatment-naive, KRAS-G12D-mutant pancreatic cancer — roughly 2.7 times the historical chemotherapy benchmark — with no dose-limiting toxicities and no treatment-related deaths or discontinuations, despite a 90.3% grade ≥3 (mostly hematologic) adverse-event rate. These are single-arm, early-phase results: a randomized phase 3 trial (NCT07232875) is now under way to confirm whether the response signal yields a survival benefit.